REFERENCES 1. U.S. Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2016 With Chartbook on Long-term Trends in Health. Available at: cdc.gov/nchs/data/hus/hus16.pdf#079. Accessed November 8, 2017. 2. Loya AM, González-Stuart A, Rivera JO. Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire-based study. Drugs Aging. 2009;26:423–436. 3. Yuan A, Woo SB. Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:35–47. 4. Tan EC, Lexomboon D, Sandborgh-Englund G, Haasum Y, Johnell K. Medications that cause dry mouth as an adverse effect in older people: a systematic review and metaanalysis. J Am Geriatr Soc. October 26, 2017. Epub ahead of print. 5. Viljakainen S, Nykänen I, Ahonen R, et al. Xerostomia among older home care clients. Community Dent Oral Epidemiol. 2016;44:232–238. 6. Aliko A, Wolff A, Dawes C, et al. World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120:185–206. 7. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:28–46. 8. Wolff A, Joshi RK, Ekström J, et al. A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the World Workshop on Oral Medicine VI. Drugs R D. 2017;17:1–28. 9. Villa A, Wolff A, Narayana N, et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis. 2016;22:365–382. 10. Miranda-Rius J, Brunet-Llobet L, Lahor-Soler E, Farré M. Salivary secretory disorders, inducing drugs, and clinical management. Int J Med Sci. 2015;12:811–824. 11. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res. 1987;66(Spec No):648–653. 12. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth — 2nd edition. Gerodontology. 1997;14:33–47. 13. Nähri TO, Meurman JH, Ainamo A. Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. Drugs Aging. 1999;15:103–116. 14. Dawes C, Pedersen AM, Villa A, et al. The functions of human saliva: a review sponsored by the World Workshop on Oral Medicine VI. Arch Oral Biol. 2015;60:863–874. 15. Brown T. 100 Best-Selling, Most Prescribed Branded Drugs Through March. Available at: medscape.com/viewarticle/844317. Accessed November 9, 2017. 16. U.S. Centers for Disease Control and Prevention. Antifungal Resistance. Available at: cdc.gov/fungal/antifungal-resistance.html. Accessed November 9, 2017. 17. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. Available at: www.fda.gov/Drugs/DrugSafety/ucm362415.htm. Accessed November 7, 2017. 18. DePaola LG, Spolarich AE. Safety and efficacy of antimicrobial mouthrinses in clinical practice. J Dent Hyg. 2007;81(Suppl, pt 2):13–25. 19. Riley P, Glenny AM, Hua F, Worthington HV. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy. Cochrane Database Syst Rev. 2017:7:CD012744. 20. American Dental Association. Caries Risk Assessement Form. Available at: ada.org/~/media/ADA/Science%20and%20Research/Files/topic_caries_over6.ashx. Accessed November 9, 2017. 21. Doméjean S, White JM, Featherstone JD. Validation of the CDA CAMBRA caries risk assessment — a six-year retrospective study. J Calif Dent Assoc. 2011;39:709–715. 22. American Dental Association. Professionally Applied and Prescription-strength, Home-use Topical Fluoride Agents for Caries Prevention Clinical Practice Guideline (2013). Available at: ebd.ada.org/en/evidence/guidelines/topical-fluoride. Accessed November 9, 2017. 23. Rethman MP, Beltrán-Aguilar ED, Billings RJ, et al. Nonfluoride caries-preventive agents: executive summary of evidence-based clinical recommendations. J Am Dent Assoc. 2011;142:1065–1071. 24. Papas A, Singh M, Harrington D, et al. Stimulation of salivary flow with a powered toothbrush in a xerostomic population. Spec Care Dentist. 2006;26:241–246. 25. Jinbu Y, Demitsu T. Oral ulcerations due to drug medications. Japan Dent Sci Rev. 2014;50:40–46. 26. Seymore RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol. 1996;23:165–175. 27. Fortuna G, Aria M, Schiavo JH. Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review. Eur J Clin Pharmacol. September 13, 2017. Epub ahead of print. 28. McGuire DB, Fulton JS, Park J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3165–3177. DecisionsInDentistry.com 29. Peterson DE, Ohrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013;21:327–332. 30. Yarom N, Ariyawardana A, Hovan A, et al. Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3209–3221. 31. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:333–341. 32. Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One. 2014;9:e107418. The answer sheet and further instructions are located on the tear-out card that appears on page 37, or take the test online at DecisionsInDentistry.com. CE QUESTIONS 1. Recent statistics from the U.S. Centers for Disease Control and Prevention (CDC) reveal that what percentage of the U.S. population has taken at least one medication within the last 30 days? A. 49% B. 37% C. 31% D. 24% 2. Adverse oral drug effects include which of the following? A. Xerostomia B. Oral ulcerations C. Gingival hyperplasia D. All of the above 3. Drug-induced xerostomia or dry mouth is a rarely reported oral side effect among older adults. True False 4. Stimulation of the sympathetic nervous system produces saliva that is high in proteins, but low in what else? A. Cell-surface receptors B. Volume C. Strontium salts D. Muscarinic receptors 5. Most patients do not complain of xerostomia until what portion of the normal salivary flow is lost? A. One-quarter B. One-third C. One-half D. Three-quarters 6. Inhaled medications have been reported to produce the sensation of dry mouth without actually altering salivary flow rates. True False 7. Due to the loss of natural salivary immunoglobulins, patients with chronic xerostomia are at high risk for a variety of oral infections, including which of the following? A. Bacterial B. Fungal C. Viral D. All of the above 8. Numerous interventions exist to assist patients with restoring oral comfort and function, and to reduce what else associated with chronic xerostomia? A. Bleeding gingiva B. Adverse oral sequelae C. Migraines D. Pulpal involvement 9. Approximately how many drugs have been associated with altering taste (dysgeusia) and smell (dysosmia)? A. > 250 B. ≤ 225 C. < 200 D. ≤ 175 10. Although many others have also been implicated, common medications associated with lichenoid drug reaction include which of the following? A. Nonsteroidal anti-inflammatory drugs B. Antihypertensive agents C. A and B D. None of the above December 2017 • Decisions IN DENTISTRY 33
